Copyright
©The Author(s) 2021.
World J Gastroenterol. Jul 21, 2021; 27(27): 4383-4394
Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4383
Published online Jul 21, 2021. doi: 10.3748/wjg.v27.i27.4383
Figure 1 Case example of a 60-year-old man with borderline resectable pancreatic cancer initially treated with FOLFIRINOX.
A: Computed tomography image; B: Carbohydrate antigen 19-9 after two months increased so was switched to Gemcitabine/Abraxane with resultant decrease in tumor markers. Given low involvement of superior mesenteric vein, chemoradiation given prior to surgical resection. CA 19-9: Carbohydrate antigen 19-9.
- Citation: Hamad A, Brown ZJ, Ejaz AM, Dillhoff M, Cloyd JM. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. World J Gastroenterol 2021; 27(27): 4383-4394
- URL: https://www.wjgnet.com/1007-9327/full/v27/i27/4383.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i27.4383